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Abstract: 
Atrial fibrillation (AF) is the most common sustained arrhythmia in the general 
population. As an age-related arrhythmia AF is becoming a huge socio-economic 
burden for European healthcare systems. Despite significant progress in our 
understanding of the pathophysiology of AF therapeutic strategies for AF have not 
changed substantially and the major challenges in the management of AF are still 
unmet. This lack of progress may be related to the multifactorial pathogenesis of atrial 
remodeling and AF that hampers the identification of causative pathophysiological 
alterations in individual patients. Also, again new mechanisms have been identified 
and the relative contribution of these mechanisms still has to be established. In 
November 2010, the European Union launched the large collaborative project 
EUTRAF (=European Network of Translational Research in Atrial Fibrillation) to 
address these challenges. 
The main aims of EUTRAF are to study the main mechanisms of initiation and 
perpetuation of AF, to identify the molecular alterations underlying atrial remodeling, 
to develop markers allowing to monitor this processes and suggest strategies to treat 
AF based on insights in newly defined disease mechanisms. This article reports on the 
objectives, the structure and initial results of this network. 
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1. Current challenges in AF management and resulting research questions 
The increase in life expectancy and recent improvements in treatment of acute heart 
disease have resulted in a major increase in the number of patients suffering from 
heart failure and atrial fibrillation (AF). AF is most the common sustained arrhythmia 
in the population occurring in 1 to 2% of the general population. More than 6 million 
Europeans suffer from this arrhythmia and in an ageing society this number is 
expected to rise quickly. AF is associated with an increased risk of stroke, dementia, 
heart failure and death (1,2). In Europe, one percent or even more of the health care 
budget is spent on AF management (3). Although the socio-economic burden of AF is 
growing steadily and significant progress has been made in understanding the 
pathophysiology of this arrhythmia, treatment of AF patients is still far from 
satisfactory. The success rate of cardioversion is still limited and anti-arrhythmic 
drugs are unable to prevent recurrences of AF. Prevention of thromboembolic events 
requires anticoagulation therapy with all the associated risks. Radio-frequency 
ablation, originally developed for treatment of paroxysmal AF, is not as effective in 
persistent AF and is associated with potentially serious procedural risks (4).  
The authors believe that the relative slow progress in the development of 
antiarrhythmic, ablation and upstream AF therapies over the past years largely reflects 
our inability to identify the leading molecular mechanisms of the atrial remodeling 
process and the occurrence of AF in an individual patient.  
The central objective of the large collaborative project EUTRAF (European Network 
for Translational Research in Atrial Fibrillation) is (1) to identify these main 
molecular mechanisms of AF progression, (2) to develop serum, imaging and 
electrophysiological markers allowing to monitor this processes and (3) develop 
strategies to treat AF based on insights in these disease mechanisms.  
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2. Mission statement of EUTRAF 
The “European Network for Translational Research in Atrial Fibrillation” (EUTRAF) 
is a framework programme 7 large collaborative project supported by the European 
Union. 
EUTRAF’s general mission is to improve the management of AF in Europe. To 
achieve this, methods for identification of patients who are at-risk for AF at an early 
stage need to be developed and a better understanding of the factors leading towards 
persistent AF need to be obtained. Also, accurate diagnostic tools for identification of 
disease mechanisms in an individual patient and new therapies for each patient based 
on these individual disease mechanisms have to be defined.  
More specifically EUTRAF will 
- provide a multidisciplinary understanding of the diverse pathophysiological 
mechanisms of AF on the molecular, cellular, tissue and organ level. 
- integrate this knowledge into understanding of the electrophysiological mechanisms 
initiating and perpetuating AF. 
- identify and validate markers for the main molecular mechanisms of AF that can be 
used in patients. 
- propose a classification of AF that integrates major disease mechanisms and the 
electrophysiological characteristics of the fibrillating atria. 
- develop new therapeutic strategies targeting individual disease mechanisms. 
- disseminate the knowledge about new diagnostic tools and therapeutic techniques in 
the public domain. 
 
3. Participants and structure of EUTRAF 
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EUTRAF is a multidisciplinary consortium of expert groups involved in AF research. 
It was granted an amount of 12 million €. The total project budget is 16 million €. The 
programme was launched in November 2010. The active funding period will end by 
the end of October 2015.    
The consortium consists of academic research groups and industry partners. Expertise 
ranges from molecular biology, genetics and experimental electrophysiology, to 
engineering, computer science and cardiology. EUTRAF partners work in a matrix 
structure organized around central work packages each of which will utilize the full 
range of expertise provided by the network.  
The consortium is led by Professor John Camm from St. George‘s University of 
London (UK). Table 1 gives the list of the academic and industrial partners.  
The central objective of EUTRAF is to define the main biological mechanisms that 
lead to the slow but progressive process of atrial remodeling increasing the propensity 
to AF. This atrial disease together with the molecular remodeling occurring as a 
consequence of AF determine the progression of AF from paroxysmal to persistent 
forms of the arrhythmia (figure 1).  
Figure 2 shows the organizational structure of EUTRAF. The basic research 
undertaken to define the genetic, molecular, cellular and structural mechanisms of 
atrial remodeling are investigated in 5 basic research work packages (WPs). Apart 
from new insights into the mechanisms of AF these WPs deliver new biomarkers and 
new therapeutic targets for AF. These suggestions are explored in two clinical work 
packages, one of which focuses on new diagnostic tools for AF classification while in 
others new therapeutic approaches are investigated. Data analysis and integration is 
accommodated in an eighth work package, which at the same time serves as IT 
platform. The consortium has access to several data sets of large clinical trials that are 
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used for marker validation (e.g. Flec-SL, EAST-Trial, Anti-PAF, Maastricht-Study) 
(5-8). The ideas developed by EUTRAF partners have also led to the initiation of new 
clinical investigations as add-on studies on existing trials, new cohorts or new 
interventional trials.   
 
4. Main research objectives and recent achievements  
 
This section describes per work package (WP) examples of research projects 
undertaken by EUTRAF partners in attempt to unravel new mechanisms of AF, to 
relate them to clinical signs and symptoms, to develop new diagnostic tools for AF 
und to improve current therapeutics strategies. 
 
4.1. WP1: Extracellular matrix and structure-function relationship  
WP1 addresses questions related to the structural determinants of conduction 
disturbances in atrial muscle. Adverse heterocellular crosstalk between cardiac 
stromal and parenchymal cells at the structural, mechanical, humoral and electrotonic 
level are likely to contribute to arrhythmogenesis in fibrotic hearts. Among the 
different modalities of stroma-parenchyme interactions, it was found that mechanical 
strain acting on myofibroblasts that are electrotonically coupled to myocytes causes 
substantial slowing of impulse conduction because of activation of stretch sensitive 
channels in myofibroblasts resulting in a secondary depolarization of coupled 
myocytes (9). At physiological levels of strain, as encountered in end-diastole, this 
mechanism slowed conduction by up to 30%. With respect to humoral interactions, it 
was found that the main growth factor involved in cardiac fibrotic tissue remodeling, 
transforming growth factor-β1 (TGF-β1), substantially aggravates the arrhythmogenic 
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effect of myofibroblasts on electrotonically coupled myocytes. While TGF-β1 had 
little effect on conduction in myocyte preparations, it caused significant conduction 
slowing and increased ectopic activity in a fibrosis model (figure 3). In this model 
TGF-β1 produced a reduction of the membrane polarization of myofibroblasts that 
caused secondary depolarization of cardiomyocytes. Together, the findings suggest 
that arrhythmogenesis in fibrotic hearts in the context of mechanical stress and 
humoral factors may be dependent on myofibroblasts acting as primary ‘sensors’ that 
signal to adjacent myocytes through gap junctional coupling.  
Fibroblasts and myofibroblasts can not only crosstalk to atrial myocytes but also to 
adipocytes located in the epicardial fat tissue (EAT) or infiltrating the myocardium. 
This cell type is an important source of adipokines that can diffuse freely in the 
neighboring atrial myocardium. EUTRAF partners found that human EAT secretes 
activin A, a member of the TGF-β family, that has a marked fibrotic effect on the 
atrial myocardium by stimulating myofibroblasts. This observation raises the question 
which clinical conditions are associated with an abnormal biological activity of EAT 
which could contribute to the formation of the AF substrate. During heart failure, for 
example, EAT secretes activin A in abundance which could explain the prominent 
role of fibrosis in the pathogenesis of AF in this clinical setting (10).  
 
4.2. WP2: Ion channel remodeling and Ca2+ handling 
Primary objective of WP2 is the characterization of molecular indicators 
(‘biomarkers’) and regulators of abnormal function of ion channels in the context of 
AF. For example, EUTRAF partners could show that shear stress increases membrane 
availability of the Kv1.5-subunit underlying the ultrarapid delayed rectifier current 
(IKur) from subcellular pools through an integrin-dependent pathway, thereby 
8  
shortening atrial action potential duration (11). Activation of the integrin pathway that 
enhances Kv1.5 trafficking, may explain the increase in IKur despite reduced total 
Kv1.5 during chronic hemodynamic overload. This highlights that not only the shape 
of the action potential (12) but also the spatial distribution of ion channel pore units 
play an important role in AF-related ion-current remodeling. There is also 
accumulating evidence for altered intracellular Na+-handling and downstream Na+-
dependent ion-channel regulation in AF. In a collaboration between EUTRAF 
partners, it was identified that both IK1 and IK,ACh are regulated by intracellular Na+ in 
human atrial myocytes of SR patients, whereas Na+-dependent regulation of IK,ACh 
was lost in chronic AF patients (13). Recent EUTRAF studies have identified Ca2+-
handling abnormalities including increased sarcoplasmic reticulum (SR) Ca2+-leak 
and spontaneous SR Ca2+ releases leading to delayed afterdepolarizations in AF 
patients (Ca2+ handling instability). However, the molecular underpinnings of Ca2+-
handling abnormalities were distinct between paroxysmal AF (increased SR Ca2+-
uptake, SR Ca2+-load, RyR2 expression, and RyR2 open probability; unaltered 
Na+/Ca2+-exchanger) and chronic AF (unaltered SR Ca2+-load, and RyR2 expression; 
increased RyR2 phosphorylation, RyR2 open probability and NCX) (14,15). On the 
other hand, sustained tachycardia and AF as such have also been demonstrated to 
induce a pattern of changes which reduce the likelihood of Ca2+ related proarrhythmic 
cellular events (Ca2+ signaling silencing) (16). It is currently unclear whether Ca2+ 
instability or Ca2+ handling silencing prevails in patients with AF. Although these 
studies have identified novel factors potentially contributing to AF pathophysiology it 
needs to be established whether and how identification of these mechanisms in an 
individual patient can be used to tailor AF therapy.  
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4.3. WP3: Etiological diversity of AF 
Many patients with clinical AF suffer from underlying heart disease. Hypertension, 
heart failure, diabetes and ageing are all strong predictors of AF. Accumulation of 
clinical factors increases the individual risk of developing AF by adding to AF 
complexity, presumably via diverse pathophysiological processes related to the 
underlying conditions. As mentioned above, this etiological diversity may 
significantly contribute to the limited efficacy of rhythm control therapies. As 
proposed in a recent consensus paper (17), a classification based on underlying 
pathophysiology to guide AF therapy may be a superior strategy towards successful 
outcome.  
EUTRAF partners have invested considerable efforts in the development of risk 
factor-based AF models to systematically identify disease-specific mechanisms of AF. 
The focus is on intracellular calcium, hypertrophic and fibrotic signaling pathways as 
primary mechanisms for the initiation and progression of AF. By comparing these 
mechanisms between animal models of diverse etiology at different stages of the 
disease process, the ultimate aim is to identify substrate-specific biomarkers related to 
the pathology and stage of the underlying disease to optimize early diagnosis and 
therapeutic strategies.  
Established animal models include rat models with genetic hypertension or diabetes. 
These models are particularly suitable for long-term studies addressing the underlying 
mechanisms and complex interactions between ageing and disease-specific 
progression of AF. For instance, atria from hypertensive or diabetic rats show distinct 
age- and disease-dependent alterations in cellular and subcellular calcium homeostasis 
potentially contributing to both the substrate and the trigger for atrial 
tachyarrhythmias. In hypertensive rats, atrial hypertrophy and fibrosis develops 
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independent of age and gender. At the molecular level, there is a significant 
upregulation of genes that belong to the hypertrophic program. The most striking 
feature in atria of diabetic rats was apoptosis, which may be one of the mechanisms 
involved in the loss of contractile mass and function in diabetic cardiomyopathy. 
Very few animal studies address the interaction between AF-induced remodeling and 
disease-specific remodeling during the development of the AF substrate. For this 
reason, we have established a pig model that combines AF with hypertension. The 
combined model develops a much more severe phenotype in terms of structural 
remodeling compared to ´lone` AF (rapid pacing in the absence of hypertension). This 
is associated with faster onset and progression of sustained AF, and a higher mortality 
rate. This model is very useful for the identification of specific signaling pathways 
involved in hypertension-induced structural remodeling stabilizing AF. Once 
validated, the model may be of high value to test the efficacy of new antiarrhythmic 
drugs in settings of hypertension. 
 
4.4. WP4: Atrial metabolic and redox alterations in AF 
In many patients and in animal models, AF becomes more stable over time and 
restoration of sinus rhythm correspondingly more difficult. The reason for this lies in 
progressive, structural and functional remodeling of the atria. In a goat model of AF, 
we demonstrated that this increase in AF stability corresponds with endomysial 
fibrosis in the thin epicardial layer of the atria, leading to a more complex, 3-
dimensional pattern of fibrillatory conduction (18). Ideally, the progression of AF that 
results from functional and structural remodeling should be prevented by upstream 
therapy. A relevant target for such treatment strategies is the nitric oxide-redox 
imbalance in the fibrillating atrial myocardium. Our findings indicate that the 
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mechanisms responsible for this imbalance change with the duration of AF. In the 
first weeks of AF, activity and expression of NOX2 are upregulated in the left atrial 
myocardium. However, in later stages (months of AF), the oxidase systems 
underlying the increase in reactive oxygen species in both atria shift from NOX2 to 
mitochondrial oxidases and uncoupled nitric oxide synthases (19). Correspondingly, 
ex vivo incubation of atrial tissue with atorvastatin inhibits atrial Rac1 and NOX2 
activity in right atrial samples from patients who develop AF after cardiac surgery, 
but does not affect atrial reactive oxygen species production and nitric oxide synthase 
activity in a patients with permanent AF (20). This implies that NOX2 inhibition by 
drugs such as statins may be only effective in preventing new-onset AF or early AF-
induced electric remodeling of the atrial myocardium. Indeed, in patients undergoing 
cardiac surgery, atrial superoxide and peroxynitrite levels were independently 
associated with an increased risk of post-operative AF and preoperative atorvastatin 
treatment for 3 days was sufficient to lower atrial NOX2 activity and superoxide level 
before changes in LDL cholesterol developed. 
Remodeling of atrial myocytes during AF is ultimately caused by altered 
transcriptional regulation in the nucleus. Nuclear Ca2+ plays an important role in 
regulation of transcription and it is well known that cytoplasmic Ca2+ handling 
changes dramatically in AF (21). Whether there is also nuclear Ca2+ remodeling in 
AF is unknown. Therefore, another aim is to characterize potential nuclear Ca2+ 
remodeling in AF (e.g. with regard to IP3 signaling) (22) and to evaluate its role in 
atrial myocyte remodeling. Identifying and understanding such changes holds the 
promise to identify novel upstream therapy targets. 
Another related factor is the balance between atrial energy/ oxygen demand and 
supply. Little is known about how atrial oxygen supply responds to increased demand, 
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and under which conditions it falls short (supply-demand mismatch). We have 
recently reported that in normal healthy pigs the left atrium has a lower coronary flow 
reserve than the left ventricle, but a higher oxygen extraction reserve (23). Although 
both reserves were recruited during short-term AF, a supply-demand mismatch, as 
evidenced by increased lactate production, still arose in the left atrium. This 
imbalance may form a pivotal trigger that induces atrial structural changes on the 
longer term, and may therefore represent another interesting target for upstream 
therapy. 
 
4.5. WP5: Genetic causes of AF 
Atrial fibrillation shows familial clustering, and common genetic variants on 
chromosome 4q25 (and others) are associated with AF. To further understand the 
mechanisms conveying AF in patients with genetic variations, we studied a mutation 
that increases the late sodium current, characterised the effects of increased 
expression of CREM in a mouse model of spontaneous AF. We also investigated the 
functional and gene expression effects of reducing pitx2, the gene that is closest to the 
genetic variants on chromosome 4q25.  
Patients with long QT syndrome develop short-lasting atrial arrhythmias triggered by 
“atrial afterdepolarizations” (24,25). A unique genetic model expressing a knock-in 
mutation of the cardiac sodium channel with an exclusive increase in late sodium 
current (D-KPQ-SCN5A knockin) allowed us to demonstrate that prolongation of the 
atrial action potential, early afterdepolarizations and pause-dependent atrial 
arrhythmias explain this monogenic form of AF (26).  
The myocyte-directed expression of the splice variant CREM-IbΔC-X of transcription 
factor CREM in mice (CREM-TG) led to spontaneous-onset AF associated with an 
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increased CamKII mediated phosphorylation of RyR2 (24-26). EUTRAF partners 
described an arrhythmogenic substrate preceding AF in CREM-TG mice: Atrial 
remodeling occurred at week 3 of age characterized as a distension of atria with thin 
atrial walls of disorganized and elongated cardiomyocytes (27). The atrial remodeling 
represents a key event in the development of AF in this model that precedes the 
occurrence of AF and is associated with atrial ectopics and triggering of AF episodes 
by programmed stimulation in young transgenic mice. Functional changes in CREM-
TG atria are related to the electrophysiological properties of atrial myocytes and 
further alterations suggesting that Ca2+-dependent mechanisms also contribute to the 
development of AF. Therefore, the expression of CREM-IbΔC-X in mice triggers 
mutually dependent changes in morphology, electrophysiological properties and regu-
lation of intracellular calcium in atrial myocardium which highlights important 
aspects of human AF. Interestingly, β-adrenoceptor stimulation provokes a >50-fold 
up-regulation of novel CREM isoforms (smICER) which leads to the translation of 
the very same or similar CREM repressors as arise from CREM-IbΔC-X (28). Hence, 
data from CREM-TG mice leads to the hypothesis that plasma catecholamines 
contribute to the pathogenesis of AF by triggering the induction of CREM repressors.  
We also studied pitx2 expression as a marker for “leftness” in the atria. We used a 
mouse model with reduced expression of pitx2 mRNA to assess the functional and 
gene expression effects of reducing pitx2 for atrial fibrillation. We could demonstrate 
that pitx2, a paired homeobox transcription factor that is implicated in left-right 
differentiation during embryonic development, is expressed at relatively high levels in 
the adult left, but not right, atrium (29). We also found that reduced pitx2 expression 
shortens the atrial action potential, especially at short pacing cycle lengths, and 
predisposes to atrial fibrillation in the absence of gross structural atrial abnormalities 
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(29). These data already suggest that pitx2 may be relevant to maintain the left-right 
differentiation in adult atrial tissue. We identified differentially expressed genes in 
left and right atrium in mice and in human atrial tissue, and identified a list of the “top 
10” genes that differ in right and left atrial expression (30). Interestingly, half of these 
genes are differentially expressed in mouse atria with reduced pitx2 expression (30). 
We are currently working to identify whether these genes could be relevant as 
functional mediators conveying AF and/or as biomarkers to identify patients with 
“polygenic AF” (31). 
 
4.6. WP6: Classification of AF with new diagnostic tools 
WP6 of EUTRAF aims at developing non-invasive tools that may provide 
information on the relative degree of electrophysiological changes in the atria. The 
slow but steady process of structural remodeling in the atria due to ageing, structural 
heart disease or AF itself is characterized by hypertrophy, activation of fibroblasts and 
enhanced collagen deposition. The resulting increase in electrical dissociation 
between muscle bundles causes conduction disturbances with more and narrower 
fibrillation waves (32-34). There is ample evidence that this increase in the 
complexity of the conduction pattern during AF reduces the success rate of any 
rhythm control strategy. For this reason, in WP6 tools to noninvasively determine AF 
complexity have been developed. Quantification of the AF substrate by advanced 
analysis of surface ECGs appears to be a logical step towards non-invasive 
quantification of the individual degree of electropathological alterations in the atria 
(35,36). 
Within the EUTRAF consortium we developed a large software package allowing for 
quantification of multiple complexity parameters in the ECG. The analysis of AF 
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ECGs in more than 500 AF patients using this software package revealed that a 
combination of different mathematical techniques (e.g. f-wave amplitude and 
organization index of the power spectrum) and multiple leads has a higher predictive 
value for outcome than a single method on single leads. Importantly, the ECG 
predictors had a comparable or higher predictive value than established clinical 
predictors like age, gender, LV-performance, heart dimensions, or co-morbidities. 
Because of the close anatomical relation between the esophagus and the left atrial 
posterior wall, the EUTRAF consortium developed a technique to determine the 
degree of electrophysiological changes in the posterior wall of the left atrium by 
fractionation analysis of a transesophageal ECG (TE-ECG). Figure 4 demonstrates the 
excellent match between frequency and complexity of the atrial activation in the 
atrium (LA, gold standard) and the TE-ECG. This technique has recently been 
patented (EPO Patent 2526861-A1) and a valorization program for this technique has 
been initiated. In order to stimulate the process of standardization and harmonization 
of the assessment of AF complexity from surface ECG EUTRAF members hosted the 
first European Conference for Standardization of Advanced ECG Analysis in 
Arrhythmia Diagnostics focusing on Quantification of the Atrial Fibrillation Substrate 
Complexity, in Lugano, Switzerland, in December 2013. At this conference details on 
technical standards were discussed and common studies for correlating ECG 
parameters to AF mechanisms and cross-validation of AF complexity measures were 
discussed and initiated. These activities will be very useful for the development of a 
clinically useful classification of AF to determine AF mechanisms and to optimize AF 
treatment. 
 
4.7. WP7: Improving AF therapy by mechanism-based therapies 
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Treating AF through surgical or catheter ablation is based on the elimination of the 
triggers initiating the arrhythmia and/or the substrate maintaining it. In paroxysmal 
AF, ablation successfully targets triggers, which are mainly located in the pulmonary 
veins (PVs). In persistent AF results are less satisfactory, presumably because of the 
influence of wider atrial substrate for AF perpetuation (37,38). For determining a 
therapeutic strategy in persistent AF (localized target vs. global intervention), the key 
question is whether the activation waves that perpetuate persistent AF individually 
emanate from few, stable, and localized drivers or whether the waves are transitory, 
widely distributed and self perpetuating. Localized drivers are difficult to detect in 
persistent AF with conventional techniques because of limitations in technology for 
sequential mapping, high degree of electrograms fractionation, intermittent firing and 
spatial meandering of fibrillation waves (39-41). 
Recent developments have allowed biatrial AF mapping using activation or phase-
based analysis of body surface potentials. The objective of this study was to evaluate 
the ability of non-invasive mapping to identify driver-domains and characterize them 
in persistent human AF. 
In 103 consecutive patients with persistent AF, accurate bi-atrial geometry relative to 
an array of 252-body-surface electrodes was obtained from non-contrast CT-scan. The 
reconstructed unipolar AF-electrograms acquired bedside from multiple windows 
(duration: 9±1s) were signal-processed to identify the drivers (focal or re-entrant 
activity) and their cumulative density-map was constructed (Figure 5). The driver 
domains were catheter ablated using AF termination as procedural endpoint in 
comparison with stepwise-ablation control group. 
The maps showed changing beat-to-beat wavefronts and varying spatio-temporal 
behaviour of driver activities. Re-entries were not sustained (median 2.6 rotations 
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lasting 449±89ms), meandered substantially but recurred repetitively. Their locations 
could be described not as discrete sites but as regions. Totally, 4720 drivers were 
identified in 103 patients: 3802 (80.5%) re-entries and 918 (19.5%) focal discharges, 
most of them co-localized. Of these, 69% re-entries and 71% foci were located in the 
left atrium. Driver ablation alone terminated 75% and 15% of persistent and long-
lasting AF, respectively. The number of targeted driver regions increased with the 
duration of continuous AF: 2 in patients presenting in sinus rhythm, 3 in AF 1-
3months, 4 in AF 4-6months and 6 in AF lasting longer. Termination rate sharply 
declined after 6 months of AF. At 6 months after the ablation, 83% patients with AF-
termination were free from AF, similar to control population undergoing step-wise 
AF ablation (84%,).  
The non-invasive system can map AF before the procedure and help to shorten 
invasive procedural time by identification of AF drivers. The functional role of the 
regions hosting drivers is demonstrated by prolongation of fibrillatory cycle length 
during their ablation and AF termination in the majority of patients. This driver based 
ablation strategy by being more focused allows for a high AF termination rate with 
significant reduction in radiofrequency-energy-delivery when compared to stepwise 
ablation. Earlier ablations are to be recommended as they ensure the best clinical 
outcome with limited tissue destruction. 
 
4.8. WP8: Insights in AF mechanisms derived from information science and 
analysis of large scale data sets 
Analysis of large data sets offers the opportunity to validate markers identified in a 
hypothesis-driven approach but also find new associations by hypothesis-free 
strategies, for example by using data mining techniques. The first objective of large-
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scale data analysis is standardized and scalable data collection, for which a proper IT 
infrastructure was implemented in the EUTRAF project, providing an integrated 
environment for data collection and data warehousing. This system was implemented 
on an Oracle data warehouse and Sharepoint 2013. An additional clustered data 
warehouse was built on-site for the TRAF (Turkish Atrial Fibrillation Database) 
registry in the Social Security Institution of Turkey based on the Microsoft SQL 
Server Enterprise 2013 database, on which the associated Analysis Services module 
was run for data analysis.  The required security and privacy mechanisms for all the 
above-mentioned tools have been developed and implemented to provide 
confidentiality of patient specific information and to address ethical issues based on 
EU directives. 
Following the data collection step, we proceeded with data pre-processing and data 
cleaning followed by the actual data analysis using various data mining techniques 
(42,43). The objective was to discover mechanistic relationships between biomarkers 
and the development and perpetuation of AF, to assess the predictive value of existing 
biomarkers, and to reveal new valuable biomarkers as well as new therapeutic targets. 
Through collaborations with 5 different groups in the EUTRAF consortium as well as 
the German Network of Excellence for Atrial Fibrillation (AF-NET), we analyzed the 
Flec-SL and ANTIPAF clinical datasets as well as datasets collected by the 
University of Dresden (APDRS) and Maastricht University. Finally, with the 
collaboration of MITS, St. George’s University London, and the University of Leeds, 
we have built and analyzed the largest national cohort of AF patients worldwide, the 
TRAF (Turkish Registry in Atrial Fibrillation) database.  
Analysis of the Flec-SL database through machine learning techniques has revealed 
that successful pharmacological conversion prior to the beginning of the survey 
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period had the greatest effect in predicting whether a patient would reach the primary 
endpoint (conversion to persistent AF or mortality). Data mining on the ANTIPAF 
dataset revealed strong relationships between the glomerular filtration rate, serum 
creatinine, blood urea nitrogen, and age. The TRAF dataset contains the records of 
545,000 patients who had the diagnosis of non-valvular AF according to ICD-10 code 
I48, within the years 2008-2012. TRAF is extracted from a claims and utilization 
management system called MEDULA which processes claims for all health insurance 
funds in Turkey since 2007. Analysis of the TRAF dataset has revealed that warfarin 
significantly increases the rates of hospitalization, and mortality in the low risk groups 
(CHA2DS2VASc<2) and decreases hospitalization and mortality in high risk groups 
(CHA2DS2VASc>=2). The same conclusion also holds true for the ischemic 
stroke/thromboembolism/mortality endpoint. Hemorrhagic stroke and major bleeding 
rates were found to be increased with warfarin in all risk categories. Further analyses 
have also included the predictive performance of the CHADS2 and CHA2DS2VASc 
scores, effect of comorbidities on the progression of AF and the analysis of lone AF.  
All of these studies will merge and culminate with the development of a data-mining 
based model and pertaining clinical decision support system (CDSS) to assess the risk 
of AF and its complications, which is the final innovative and scientific objective of 
the work package.  
 
5. Outlook 
The authors believe that the scientific achievements of the EUTRAF consortium was 
and will be tremendously helpful for developing better understanding of the general 
pathophysiology of AF. Hopefully, this understanding will facilitate the development 
of future therapeutic strategies, such as ion channel blockers, upstream therapy, or 
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ablation of AF. Some of these concepts are currently tested in clinical trials (table 2). 
While potentially proving useful in clinical practise, these concepts evolved along the 
traditional flow of explorative clinical or experimental evaluation, integration in 
general understanding of pathophysiology, identification of a therapeutic target and 
validation in clinical trials (figure 7A).  
For the future, we foresee a shift in this strategy towards emphasis on individual 
disease mechanisms. We acknowledge that individual components of 
pathophysiological processes leading to AF, although assessable by experimental 
research, as yet have hardly had an impact on the choice of the therapeutic option. 
Experimental research within EUTRAF but also in many other projects has shown 
that inflammation, fibrosis, reactive oxygen species activation, or fatty infiltration can 
all contribute to the development and perpetuation of AF. However, these 
considerations are usually not taken into account in the choice for an individual 
therapy. The reasons are manifold and include the presence of multiple mechanisms 
and temporal variability of pathomechanisms in an individual patient. Also the 
individual genetic background, with the exception of monogenetic cardiac diseases, is 
usually not considered in the decision on a therapeutic strategy. To overcome this 
‘translational gap’ is one of the most important challenges in the development of a 
strategy for personalized AF therapy. A potential approach to this is shown on figure 
7B.  
The authors assume that in order to identify the main mechanisms responsible for 
atrial remodeling and AF and in order to determine the relative contribution of the 
different disease mechanisms a combined histological, biochemical and complex 
genetics approach is required. In this scenario it is essential that blood samples and 
atrial tissue is available in order to detect the molecular mechanisms leading to AF. At 
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the same time, detailed clinical characterization of the patients is required so that the 
molecular mechanisms can be correlated to clinical signs and symptoms.  
From blood samples, common gene variants (SNPs) and a list of predefined 
biomarkers would need to be determined. Histological investigation of the tissue will 
show degree and distribution of fibrosis, amyloidosis, fatty infiltration, vascular 
rarefaction, inflammation and other mechanisms. Biochemical studies will reveal 
ROS production, ion channel alterations, and activity of prohypertrophic, profibrotic, 
and proinflammatory pathways (e.g. RAS, TGF-β1). Gene-expression profiling could 
be used to identify differentially expressed genes informing on statistically enriched 
signaling pathways. The information from all these investigations will allow for 
identification of the ‘leading molecular mechanisms’ in a specific patient. Preferably, 
the mechanisms should be identified on the tissue or biochemical pathway level. In a 
second step, a mathematical model to detect the leading molecular mechanisms from 
parameters measured in blood samples, ECGs, echocardiography, and clinical profile 
could be constructed. From blood samples, ECGs, echocardiography, and clinical 
profile information of the same patients (the patients from whom atrial tissue was 
obtained) a large number of  ‘features’ would be determined in each patient. A feature 
can be, for example, gender, age, LA size, comorbidity, a common gene variant, 
elevation of a biomarker, upregulation of a miRNA, an ECG parameter, or a 
medication. From all this information a model is constructed that assigns a patient to 
the correct leading molecular mechanisms based on a selection of features. At the end 
of this step, it is possible to read out the leading molecular mechanisms from a 
(hopefully) limited list of parameters that can be determined from blood, ECGs, 
echocardiography, or clinical profile of the patients. 
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The ultimate goal of this approach is to develop a classification of AF which is based 
on clinical symptoms and signs and a hopefully short list of biomarkers but which 
informs on leading pathophysiological mechanism of AF in a specific patient 
allowing for therapy tailored to these mechanisms. This shift in approach would mean 
to replace clustering patients in larger groups assumed to have developed comparable 
disease mechanisms by detecting their individual disease mechanisms. Instead 
treating them according to guidelines, decision support systems could help to identify 
the optimal therapy in an individual patient.  
Such strategies are more than a daydream. They have been implemented in 
personalized medicine strategies in various chronic diseases such as Alzheimer’s 
disease or some forms of cancer (44-46). Increasing restrictions in health care budgets 
call for reinforcement of personalized approaches also in cardiovascular diseases. 
Taking advantage of their broad and translational expertise EUTRAF partners are 
well positioned to deliver significant contributions to this process. 
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Table 1 
St-George’s University of London (UK) 
Maastricht University (The Netherlands) 
Université Pierre Marie Curie – Paris (France) 
Technische Universität Dresden (Germany) 
Centre Hospitalier Universitaire – Bordeaux (France) 
Westfälische Wilhelms-Universität Münster (Germany) 
University Hospital Magdeburg (Germany) 
Universität Bern (Switzerland) 
University Hospital Graz (Austria) 
Medical Information Technology Solutions (Turkey) 
University of Oxford (UK) 
UK Health & Environment Research Institute (UK) 
Sanofi-aventis Deutschland GmbH (Germany) 
Osypka AG (Germany) 
Xention Ltd (UK) 
Universität Duisburg-Essen – Essen (Germany) 
Philipps Universität – Marburg (Germany) 
Ernst-Moritz-Arndt Universität – Greifswald (Germany) 
 
Table 1: Institutions participating in EUTRAF 
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Table 2 
Study title / 
acronym 
Organizing 
partner site 
Number of 
patients  
Research objective 
MULTI-AF UM 220 Predictive value of new ECG and biomarkers in patients 
undergoing electrical cardioversion 
PROTON UM 40 Identification of rotors during AF by sinusoidal 
recomposition and Hilbert transform of endocardial 
electrograms in patients undergoing catheter ablation for 
AF 
MAPAC UM 150 Direct contact mapping of patients undergoing open chest 
surgery, correlation of conduction disturbances with 
tissue-, serum-, and ECG markers 
Late-POAF UM 100 Identification of tissue-, serum-, and ECG-markers for 
incident AF in SR patients undergoing open chest surgery.  
STICS Oxford 1922 Randomised, double-blind, placebo-controlled trial of the 
effect of perioperative rosuvastatin on postoperative AF 
and myocardial damage  
TRAF Ankara 545000 TRAF (Turkish Atrial Fibrillation Database) registry in the 
Social Security Institution of Turkey. 
Association between comorbidities, medication, and 
hospitalization with progression of AF and stroke. 
 
Table 2: Ongoing clinical studies testing scientific concepts developed by EUTRAF 
partners. 
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Figure Legends: 
 
Figure 1: EUTRAF’s main objective is to unravel the molecular mechanisms causing 
progression from paroxysmal to persistent AF in relation to the underlying etiological 
factors. 
 
Figure 2: Organizational structure of EUTRAF. The research topics are explained in 
more detail in section 4. 
 
Figure 3: Precipitation of sustained reentrant activity in models of fibrotic 
myocardium (myocyte monolayers coated with myofibroblasts). Spontaneously 
arising functional reentry (central disc, 800 µm diameter) is, in some preparations, 
accompanied by anatomical reentry (peripheral ring of tissue, separated by a gap from 
the central disc). The frequency of reentrant activity in the 6 preparations shown 
ranged from 3 to 8 Hz (voltage sensitive dye recordings). 
 
Figure 4: Excellent match between atrial activations (red A) in the left atrial posterior 
wall (upper tracing) and the TE-ECG (mid tracing). Please note, that the atrial 
deflections show a low complexity (low fractionation index) in both LA-electrograms 
as well as in the TE-ECG on the left and a high degree of fractionation (high number 
of small high frequency deflections) in the right part of the tracing. Such differences 
are not seen in the surface ECG.  
 
Figure 5: Vest carrying 252 electrodes placed on the patient’s chest (A) during CT 
scan (B) to reconstruct cardiac activation which is then analyzed with a phase 
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mapping algorithm (C). A rotor is seen on that map (arrow). The rotors and foci are 
then displayed on cumulative maps (D) to identify the most active region and 
hierarchize the ablation. 
 
Figure 6: Overcoming the translational gap between knowledge on mechanisms 
responsible for AF – often assessed by experimental research and the results of 
clinical investigations (A) forms an important challenge for the future. Detection of 
individual disease mechanisms by markers or parameters which can easily be 
measures in every patients and which at the same time inform on the relevant disease 
processes are required to close the translational gap and to develop an individualized 
therapeutic approach. 
 
 
 
 
  
27  
References 
 
1. Bos MJ, Koudstaal PJ, Hofman A, Ikram MA. Modifiable etiological factors 
and the burden of stroke from the Rotterdam study: a population-based cohort 
study. PLoS Med. 2014;11:e1001634.  
2. Rienstra M, McManus DD, Benjamin EJ. Novel risk factors for atrial 
fibrillation: useful for risk prediction and clinical decision making? Circulation. 
2012;125:e941–e946.  
3. Stewart S, Murphy NF, Murphy N, Walker A, McGuire A, McMurray JJV. 
Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the 
UK. Heart. 2004;90:286–292.  
4. Dewire J, Calkins H. Update on atrial fibrillation catheter ablation technologies 
and techniques. Nat Rev Cardiol. 2013;10:599–612.  
5. Goette A, Schön N, Kirchhof P, Breithardt G, Fetsch T, Häusler KG, Klein HU, 
Steinbeck G, Wegscheider K, Meinertz T. Angiotensin II-antagonist in 
paroxysmal atrial fibrillation (ANTIPAF) trial. Circ Arrhythm Electrophysiol. 
2012;5:43–51.  
6. Kirchhof P, Andresen D, Bosch R, Borggrefe M, Meinertz T, Parade U, 
Ravens U, Samol A, Steinbeck G, Treszl A, Wegscheider K, Breithardt G. 
Short-term versus long-term antiarrhythmic drug treatment after cardioversion 
of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded 
endpoint assessment trial. Lancet. 2012;380:238–246.  
7. Schram MT, Sep SJS, van der Kallen CJ, Dagnelie PC, Koster A, Schaper N, 
Henry RMA, Stehouwer CDA. The Maastricht Study: an extensive 
phenotyping study on determinants of type 2 diabetes, its complications and its 
comorbidities. European journal of epidemiology. 2014;29:439–451.  
8. Kirchhof P, Breithardt G, Camm AJ, Crijns HJ, Kuck K-H, Vardas P, 
Wegscheider K. Improving outcomes in patients with atrial fibrillation: 
rationale and design of the Early treatment of Atrial fibrillation for Stroke 
prevention Trial. Am Heart J. 2013;166:442–448.  
9. Grand T, Salvarani N, Jousset F, Rohr S. Aggravation of cardiac myofibroblast 
arrhythmogeneicity by mechanical stress. Cardiovasc Res. 2014;104:489–500.  
10. Venteclef N, Guglielmi V, Balse E, Gaborit B, Cotillard A, Atassi F, Amour J, 
Leprince P, Dutour A, Clément K, Hatem SN. Human epicardial adipose tissue 
induces fibrosis of the atrial myocardium through the secretion of adipo-
fibrokines. European Heart Journal. 2013.  
11. Boycott HE, Barbier CSM, Eichel CA, Costa KD, Martins RP, Louault F, 
Dilanian G, Coulombe A, Hatem SN, Balse E. Shear stress triggers insertion of 
voltage-gated potassium channels from intracellular compartments in atrial 
28  
myocytes. Proc Natl Acad Sci USA. 2013;110:E3955–E3964.  
12. Schotten U, de Haan S, Verheule S, Harks EGA, Frechen D, Bodewig E, 
Greiser M, Ram R, Maessen J, Kelm M, Allessie M, Van Wagoner DR. 
Blockade of atrial-specific K+-currents increases atrial but not ventricular 
contractility by enhancing reverse mode Na+/Ca2+-exchange. Cardiovasc Res. 
2007;73:37–47.  
13. Voigt N, Heijman J, Trausch A, Mintert-Jancke E, Pott L, Ravens U, Dobrev D. 
Impaired Na⁺ -dependent regulation of acetylcholine-activated inward-rectifier 
K⁺  current modulates action potential rate dependence in patients with chronic 
atrial fibrillation. J Mol Cell Cardiol. 2013;61:142–152.  
14. Voigt N, Li N, Wang Q, Wang W, Trafford AW, Abu-Taha I, Sun Q, Wieland 
T, Ravens U, Nattel S, Wehrens XHT, Dobrev D. Enhanced sarcoplasmic 
reticulum Ca2+ leak and increased Na+-Ca2+ exchanger function underlie 
delayed afterdepolarizations in patients with chronic atrial fibrillation. 
Circulation. 2012;125:2059–2070.  
15. Voigt N, Heijman J, Wang Q, Chiang DY, Li N, Karck M, Wehrens XHT, 
Nattel S, Dobrev D. Cellular and molecular mechanisms of atrial 
arrhythmogenesis in patients with paroxysmal atrial fibrillation. Circulation. 
2014;129:145–156.  
16. Greiser M, Kerfant B-G, Williams GSB, Voigt N, Harks E, Dibb KM, Giese A, 
Meszaros J, Verheule S, Ravens U, Allessie MA, Gammie JS, van der Velden J, 
Lederer WJ, Dobrev D, Schotten U. Tachycardia-induced silencing of 
subcellular Ca2+ signaling in atrial myocytes. J Clin Invest. 2014;124:4759–
4772.  
17. Kirchhof P, Lip GYH, Van Gelder IC, Bax J, Hylek E, Kaab S, Schotten U, 
Wegscheider K, Boriani G, Brandes A, Ezekowitz M, Diener H, Haegeli L, 
Heidbüchel H, Lane D, Mont L, Willems S, Dorian P, Aunes-Jansson M, 
Blomstrom-Lundqvist C, Borentain M, Breitenstein S, Brueckmann M, Cater N, 
Clemens A, Dobrev D, Dubner S, Edvardsson NG, Friberg L, Goette A, et al. 
Comprehensive risk reduction in patients with atrial fibrillation: emerging 
diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation 
Competence NETwork/European Heart Rhythm Association consensus 
conference. Europace. 2012. p. 8–27.  
18. Verheule S, Tuyls E, Gharaviri A, Hulsmans S, van Hunnik A, Kuiper M, 
Serroyen J, Zeemering S, Kuijpers NHL, Schotten U. Loss of continuity in the 
thin epicardial layer because of endomysial fibrosis increases the complexity of 
atrial fibrillatory conduction. Circ Arrhythm Electrophysiol. 2013;6:202–211.  
19. Reilly SN, Jayaram R, Nahar K, Antoniades C, Verheule S, Channon KM, Alp 
NJ, Schotten U, Casadei B. Atrial sources of reactive oxygen species vary with 
the duration and substrate of atrial fibrillation: implications for the 
antiarrhythmic effect of statins. Circulation. 2011;124:1107–1117.  
20. Antoniades C, Demosthenous M, Reilly S, Margaritis M, Zhang M-H, 
29  
Antonopoulos A, Marinou K, Nahar K, Jayaram R, Tousoulis D, Bakogiannis 
C, Sayeed R, Triantafyllou C, Koumallos N, Psarros C, Miliou A, Stefanadis C, 
Channon KM, Casadei B. Myocardial redox state predicts in-hospital clinical 
outcome after cardiac surgery effects of short-term pre-operative statin 
treatment. J Am Coll Cardiol. 2012;59:60–70.  
21. Greiser M, Schotten U. Dynamic remodeling of intracellular Ca²⁺  signaling 
during atrial fibrillation. J Mol Cell Cardiol. 2013;58:134–142.  
22. Kockskämper J, Seidlmayer L, Walther S, Hellenkamp K, Maier LS, Pieske B. 
Endothelin-1 enhances nuclear Ca2+ transients in atrial myocytes through 
Ins(1,4,5)P3-dependent Ca2+ release from perinuclear Ca2+ stores. J Cell Sci. 
2008;121:186–195.  
23. van Bragt KA, Nasrallah HM, Kuiper M, Luiken JJ, Schotten U, Verheule S. 
Atrial supply-demand balance in healthy adult pigs: coronary blood flow, 
oxygen extraction, and lactate production during acute atrial fibrillation. 
Cardiovasc Res. 2014;101:9–19.  
24. Müller FU, Lewin G, Baba HA, Boknik P, Fabritz L, Kirchhefer U, Kirchhof P, 
Loser K, Matus M, Neumann J, Riemann B, Schmitz W. Heart-directed 
expression of a human cardiac isoform of cAMP-response element modulator 
in transgenic mice. J Biol Chem. 2005;280:6906–6914.  
25. Chelu MG, Sarma S, Sood S, Wang S, van Oort RJ, Skapura DG, Li N, 
Santonastasi M, Müller FU, Schmitz W, Schotten U, Anderson ME, 
Valderrábano M, Dobrev D, Wehrens XHT. Calmodulin kinase II-mediated 
sarcoplasmic reticulum Ca2+ leak promotes atrial fibrillation in mice. J Clin 
Invest. 2009;119:1940–1951.  
26. Li N, Chiang DY, Wang S, Wang Q, Sun L, Voigt N, Respress JL, Ather S, 
Skapura DG, Jordan VK, Horrigan FT, Schmitz W, Müller FU, Valderrábano 
M, Nattel S, Dobrev D, Wehrens XHT. Ryanodine receptor-mediated calcium 
leak drives progressive development of an atrial fibrillation substrate in a 
transgenic mouse model. Circulation. 2014;129:1276–1285.  
27. Kirchhof P, Marijon E, Fabritz L, Li N, Wang W, Wang T, Schulte K, Hanstein 
J, Schulte JS, Vogel M, Mougenot N, Laakmann S, Fortmueller L, Eckstein J, 
Verheule S, Kaese S, Staab A, Grote-Wessels S, Schotten U, Moubarak G, 
Wehrens XHT, Schmitz W, Hatem S, Müller FU. Overexpression of cAMP-
response element modulator causes abnormal growth and development of the 
atrial myocardium resulting in a substrate for sustained atrial fibrillation in 
mice. Int J Cardiol. 2013;166:366–374.  
28. Seidl MD, Nunes F, Fels B, Hildebrandt I, Schmitz W, Schulze-Osthoff K, 
Müller FU. A novel intronic promoter of the Crem gene induces small ICER 
(smICER) isoforms. FASEB J. 2014;28:143–152.  
29. Kirchhof P, Kahr PC, Kaese S, Piccini I, Vokshi I, Scheld H-H, Rotering H, 
Fortmueller L, Laakmann S, Verheule S, Schotten U, Fabritz L, Brown NA. 
PITX2c is expressed in the adult left atrium, and reducing Pitx2c expression 
30  
promotes atrial fibrillation inducibility and complex changes in gene 
expression. Circ Cardiovasc Genet. 2011;4:123–133.  
30. Kahr PC, Piccini I, Fabritz L, Greber B, Schöler H, Scheld HH, Hoffmeier A, 
Brown NA, Kirchhof P. Systematic analysis of gene expression differences 
between left and right atria in different mouse strains and in human atrial tissue. 
PLoS ONE. 2011;6:e26389.  
31. Kirchhof P, Breithardt G, Aliot E, Khatib Al S, Apostolakis S, Auricchio A, 
Bailleul C, Bax J, Benninger G, Blomstrom-Lundqvist C, Boersma L, Boriani 
G, Brandes A, Brown H, Brueckmann M, Calkins H, Casadei B, Clemens A, 
Crijns H, Derwand R, Dobrev D, Ezekowitz M, Fetsch T, Gerth A, Gillis A, 
Gulizia M, Hack G, Haegeli L, Hatem S, Georg Häusler K, et al. Personalized 
management of atrial fibrillation: Proceedings from the fourth Atrial 
Fibrillation competence NETwork/European Heart Rhythm Association 
consensus conference. Europace. 2013;15:1540–1556.  
32. Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms 
of atrial fibrillation: a translational appraisal. Physiol Rev. 2011;91:265–325.  
33. Allessie MA, de Groot NMS, Houben RPM, Schotten U, Boersma E, Smeets 
JL, Crijns HJ. Electropathological substrate of long-standing persistent atrial 
fibrillation in patients with structural heart disease: longitudinal dissociation. 
Circ Arrhythm Electrophysiol. 2010;3:606–615.  
34. Eckstein J, Zeemering S, Linz D, Maesen B, Verheule S, van Hunnik A, Crijns 
H, Allessie MA, Schotten U. Transmural Conduction Is the Predominant 
Mechanism of Breakthrough During Atrial Fibrillation: Evidence From 
Simultaneous Endo-Epicardial High-Density Activation Mapping. Circ 
Arrhythm Electrophysiol. 2013;6:334–341.  
35. Schotten U, Maesen B, Zeemering S. The need for standardization of time- and 
frequency-domain analysis of body surface electrocardiograms for assessment 
of the atrial fibrillation substrate. Europace. 2012;14:1072–1075.  
36. Lankveld TAR, Zeemering S, Crijns HJGM, Schotten U. The ECG as a tool to 
determine atrial fibrillation complexity. Heart. 2014;100:1077–1084.  
37. Cox JL, Schuessler RB, D'Agostino HJ, Stone CM, Chang BC, Cain ME, Corr 
PB, Boineau JP. The surgical treatment of atrial fibrillation. III. Development 
of a definitive surgical procedure. J Thorac Cardiovasc Surg. 1991;101:569–
583.  
38. Wokhlu A, Hodge DO, Monahan KH, Asirvatham SJ, Friedman PA, Munger 
TM, Cha Y-M, Shen W-K, Brady PA, Bluhm CM, Haroldson JM, Hammill SC, 
Packer DL. Long-term outcome of atrial fibrillation ablation: impact and 
predictors of very late recurrence. J Cardiovasc Electrophysiol. 2010;21:1071–
1078.  
39. Rostock T, Rotter M, Sanders P, Takahashi Y, Jaïs P, Hocini M, Hsu L-F, 
Sacher F, Clémenty J, Haïssaguerre M. High-density activation mapping of 
31  
fractionated electrograms in the atria of patients with paroxysmal atrial 
fibrillation. Heart Rhythm. 2006;3:27–34.  
40. Schuessler RB, Kawamoto T, Hand DE, Mitsuno M, Bromberg BI, Cox JL, 
Boineau JP. Simultaneous epicardial and endocardial activation sequence 
mapping in the isolated canine right atrium. Circulation. 1993;88:250–263.  
41. Kneller J, Zou R, Vigmond EJ, Wang Z, Leon LJ, Nattel S. Cholinergic atrial 
fibrillation in a computer model of a two-dimensional sheet of canine atrial 
cells with realistic ionic properties. Circ Res. 2002;90:E73–E87.  
42. Kurtcephe M, Güvenir HA. A Discretization Method Based on Maximizing the 
Area under ROC Curve. Int'l J Pattern Recognition and Artificial …. 2010.  
43. Guvenir HA, Kurtcephe M. Ranking Instances by Maximizing the Area under 
ROC Curve. IEEE Trans Knowl Data Eng. IEEE; 2013;25:2356–2366.  
44. Rosenblum D, Peer D. Omics-based nanomedicine: the future of personalized 
oncology. Cancer Lett. 2014;352:126–136.  
45. Ofiara LM, Navasakulpong A, Beaudoin S, Gonzalez AV. Optimizing tissue 
sampling for the diagnosis, subtyping, and molecular analysis of lung cancer. 
Front Oncol. 2014;4:253.  
46. Latta CH, Brothers HM, Wilcock DM. Neuroinflammation in Alzheimer's 
disease; A source of heterogeneity and target for personalized therapy. 
Neuroscience. 2014.  
 
